Literature DB >> 15537453

Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy.

S E Reid1, C A Reid, S H Vermund.   

Abstract

Declining drug costs and increases in international donor interest are leading to greater availability of antiretroviral treatment programmes for persons living with the human immunodeficiency virus in parts of sub-Saharan Africa. Ensuring adequate adherence to antiretroviral drug therapy is one of the principal challenges facing successful implementation in Africa, where 70% of the world's infected persons live. Tuberculosis and leprosy are two diseases of global importance whose control programmes can provide important lessons for developing antiretroviral drug adherence strategies. This paper examines various approaches used in tuberculosis and leprosy control which could help enhance adherence to antiretroviral therapy in resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537453     DOI: 10.1258/0956462042395195

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  6 in total

1.  Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia.

Authors:  Dara Potter; Robert L Goldenberg; Jennifer S Read; Jing Wang; Irving F Hoffman; Elmar Saathoff; George Kafulafula; Said Aboud; Francis E A Martinson; Maysoon Dahab; Sten H Vermund
Journal:  Sex Transm Dis       Date:  2006-10       Impact factor: 2.830

2.  Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia.

Authors:  Sten H Vermund; Sarah J Fidler; Helen Ayles; Nulda Beyers; Richard J Hayes
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

Review 3.  Co-infection with human immunodeficiency virus and tuberculosis in Asia.

Authors:  Sten H Vermund; Naoki Yamamoto
Journal:  Tuberculosis (Edinb)       Date:  2007-07-16       Impact factor: 3.131

4.  Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Authors:  Leila Essop Mansoor; Quarraisha Abdool Karim; Nonhlanhla Yende-Zuma; Kathleen M MacQueen; Cheryl Baxter; Bernadette T Madlala; Anneke Grobler; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2014-05

5.  A network-based model to explore the role of testing in the epidemiological control of the COVID-19 pandemic.

Authors:  Yapeng Cui; Shunjiang Ni; Shifei Shen
Journal:  BMC Infect Dis       Date:  2021-01-12       Impact factor: 3.090

Review 6.  Combination prevention: new hope for stopping the epidemic.

Authors:  Sten H Vermund; Richard J Hayes
Journal:  Curr HIV/AIDS Rep       Date:  2013-06       Impact factor: 5.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.